Published in Biochemistry on June 10, 2003
The ubiquitylation machinery of the endoplasmic reticulum. Nature (2009) 2.66
Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A (2004) 2.14
Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. Cell Rep (2013) 1.87
The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol (2012) 1.70
Protein aggregation and protein instability govern familial amyotrophic lateral sclerosis patient survival. PLoS Biol (2008) 1.61
Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry (2008) 1.26
The modulation of transthyretin tetramer stability by cysteine 10 adducts and the drug diflunisal. Direct analysis by fluorescence-detected analytical ultracentrifugation. J Biol Chem (2008) 1.16
Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J Med Chem (2008) 1.10
Sequence determinants of protein aggregation: tools to increase protein solubility. Microb Cell Fact (2005) 1.09
Synthesis and evaluation of transthyretin amyloidosis inhibitors containing carborane pharmacophores. Proc Natl Acad Sci U S A (2007) 1.06
A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity. J Am Chem Soc (2010) 1.02
Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention. Crit Rev Biochem Mol Biol (2012) 1.01
Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J Med Chem (2009) 0.99
Partitioning conformational intermediates between competing refolding and aggregation pathways: insights into transthyretin amyloid disease. Biochemistry (2005) 0.97
Unfolded protein response-induced ERdj3 secretion links ER stress to extracellular proteostasis. EMBO J (2014) 0.96
Endoplasmic reticulum quality control regulates the fate of transthyretin variants in the cell. EMBO J (2007) 0.95
Expression, purification, and in vitro cysteine-10 modification of native sequence recombinant human transthyretin. Protein Expr Purif (2007) 0.91
Fourier transform infrared spectroscopy provides a fingerprint for the tetramer and for the aggregates of transthyretin. Biophys J (2006) 0.91
The Endoplasmic Reticulum-associated Degradation of Transthyretin Variants Is Negatively Regulated by BiP in Mammalian Cells. J Biol Chem (2009) 0.88
Transthyretin as both a sensor and a scavenger of β-amyloid oligomers. Biochemistry (2013) 0.88
A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin. Bioorg Med Chem (2010) 0.87
Inhibition of human transthyretin aggregation by non-steroidal anti-inflammatory compounds: a structural and thermodynamic analysis. Int J Mol Sci (2013) 0.82
Amyloidogenic potential of transthyretin variants: insights from structural and computational analyses. J Biol Chem (2009) 0.82
ATF6 activation reduces the secretion and extracellular aggregation of destabilized variants of an amyloidogenic protein. Chem Biol (2014) 0.82
Enhanced Aromatic Sequons Increase Oligosaccharyltransferase Glycosylation Efficiency and Glycan Homogeneity. Chem Biol (2015) 0.81
Uptake of aggregating transthyretin by fat body in a Drosophila model for TTR-associated amyloidosis. PLoS One (2010) 0.80
Amyloidogenic propensity of a natural variant of human apolipoprotein A-I: stability and interaction with ligands. PLoS One (2015) 0.79
Endoplasmic reticulum quality control and systemic amyloid disease: Impacting protein stability from the inside out. IUBMB Life (2015) 0.78
Transthyretin Binding Heterogeneity and Anti-amyloidogenic Activity of Natural Polyphenols and Their Metabolites. J Biol Chem (2015) 0.78
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther (2016) 0.77
Lys-315 at the Interfaces of Diagonal Subunits of δ-Crystallin Plays a Critical Role in the Reversibility of Folding and Subunit Assembly. PLoS One (2016) 0.75
A current pharmacologic agent versus the promise of next generation therapeutics to ameliorate protein misfolding and/or aggregation diseases. Curr Opin Chem Biol (2016) 0.75
Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors. Bioorg Med Chem Lett (2017) 0.75
Adapting proteostasis for disease intervention. Science (2008) 13.22
A common open representation of mass spectrometry data and its application to proteomics research. Nat Biotechnol (2004) 11.42
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Opposing activities protect against age-onset proteotoxicity. Science (2006) 5.85
Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem (2009) 5.23
Semen-derived amyloid fibrils drastically enhance HIV infection. Cell (2007) 5.23
Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell (2006) 5.01
Therapeutic approaches to protein-misfolding diseases. Nature (2003) 4.57
Functional amyloid--from bacteria to humans. Trends Biochem Sci (2007) 4.50
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Functional amyloid formation within mammalian tissue. PLoS Biol (2006) 3.92
The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol (2006) 3.62
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology (2012) 3.48
Recombinant prion protein induces a new transmissible prion disease in wild-type animals. Acta Neuropathol (2010) 3.19
Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell (2008) 3.11
Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell (2009) 2.87
The biological and chemical basis for tissue-selective amyloid disease. Cell (2005) 2.76
Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A (2002) 2.71
Comparison of the methods for profiling glycoprotein glycans--HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology (2007) 2.71
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol (2009) 2.70
Genetic prion disease: the EUROCJD experience. Hum Genet (2005) 2.64
Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science (2003) 2.63
T cell activation by lipopeptide antigens. Science (2004) 2.59
An experimental survey of the transition between two-state and downhill protein folding scenarios. Proc Natl Acad Sci U S A (2008) 2.57
Context-dependent contributions of backbone hydrogen bonding to beta-sheet folding energetics. Nature (2004) 2.44
Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain (2003) 2.42
The human proteome project: current state and future direction. Mol Cell Proteomics (2011) 2.34
Structure-function-folding relationship in a WW domain. Proc Natl Acad Sci U S A (2006) 2.28
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A (2012) 2.27
Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res (2005) 2.25
Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci U S A (2002) 2.25
Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants. ACS Chem Biol (2006) 2.25
Tabulation of human transthyretin (TTR) variants, 2003. Amyloid (2003) 2.23
Mutations of the prion protein gene phenotypic spectrum. J Neurol (2002) 2.20
Tuning the free-energy landscape of a WW domain by temperature, mutation, and truncation. Proc Natl Acad Sci U S A (2003) 2.15
Fibulin-5 mutations link inherited neuropathies, age-related macular degeneration and hyperelastic skin. Brain (2011) 2.15
Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A (2004) 2.14
Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol (2011) 2.10
Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry (2004) 2.08
Amyloid-β forms fibrils by nucleated conformational conversion of oligomers. Nat Chem Biol (2011) 2.08
Mycobacterium tuberculosis pks12 produces a novel polyketide presented by CD1c to T cells. J Exp Med (2004) 1.96
Rosette-forming glioneuronal tumor of the fourth ventricle. Acta Neuropathol (2003) 1.95
TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. Mov Disord (2009) 1.95
Elimination of oxidative degradation during the per-O-methylation of carbohydrates. J Am Chem Soc (2003) 1.90
Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. Cell Rep (2013) 1.87
An adaptable standard for protein export from the endoplasmic reticulum. Cell (2007) 1.86
Electron capture dissociation initiates a free radical reaction cascade. J Am Chem Soc (2003) 1.82
ALS mutants of human superoxide dismutase form fibrous aggregates via framework destabilization. J Mol Biol (2003) 1.82
Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol (2013) 1.79
Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity. Chem Biol (2004) 1.76
Abnormal proteins can form aggresome in yeast: aggresome-targeting signals and components of the machinery. FASEB J (2008) 1.74
Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A (2013) 1.73
Determinants for dephosphorylation of the RNA polymerase II C-terminal domain by Scp1. Mol Cell (2006) 1.71
The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol (2012) 1.70
Structural details and composition of Trichomonas vaginalis lipophosphoglycan in relevance to the epithelial immune function. Glycoconj J (2008) 1.69
Software tool for researching annotations of proteins: open-source protein annotation software with data visualization. Anal Chem (2009) 1.68
Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem Biol (2005) 1.68
Tandem mass spectrometry of sulfated heparin-like glycosaminoglycan oligosaccharides. Anal Chem (2003) 1.65
Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines. J Proteome Res (2006) 1.64
Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discov (2002) 1.63
Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol (2010) 1.62
Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci Transl Med (2011) 1.62
Structural features of the acyl chain determine self-phospholipid antigen recognition by a CD1d-restricted invariant NKT (iNKT) cell. J Biol Chem (2003) 1.61
Trichomonas vaginalis lipophosphoglycan triggers a selective upregulation of cytokines by human female reproductive tract epithelial cells. Infect Immun (2006) 1.61
Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol (2006) 1.60
Severe depletion of mitochondrial DNA in spinal muscular atrophy. Acta Neuropathol (2002) 1.60
A peculiar constellation of tau pathology defines a subset of dementia in the elderly. Acta Neuropathol (2011) 1.60
Isotope-coded affinity tag (ICAT) approach to redox proteomics: identification and quantitation of oxidant-sensitive cysteine thiols in complex protein mixtures. J Proteome Res (2004) 1.58
Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. J Med Chem (2007) 1.58
Reverse transcription-associated dephosphorylation of hepadnavirus nucleocapsids. Proc Natl Acad Sci U S A (2005) 1.57
Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol (2006) 1.56
Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 1.55
Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des (2008) 1.55
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol (2013) 1.54
Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem (2004) 1.54
The core trisaccharide of an N-linked glycoprotein intrinsically accelerates folding and enhances stability. Proc Natl Acad Sci U S A (2009) 1.54
Ppm1, a novel polyprenol monophosphomannose synthase from Mycobacterium tuberculosis. Biochem J (2002) 1.54
Genesis of mammalian prions: from non-infectious amyloid fibrils to a transmissible prion disease. PLoS Pathog (2011) 1.53
Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol (2008) 1.51
Amylin proprotein processing generates progressively more amyloidogenic peptides that initially sample the helical state. Biochemistry (2008) 1.51
Glycoform quantification of chondroitin/dermatan sulfate using a liquid chromatography-tandem mass spectrometry platform. Biochemistry (2006) 1.51
Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest (2004) 1.50
Engineering a beta-sheet protein toward the folding speed limit. J Phys Chem B (2005) 1.49
Endoplasmic reticulum stress features are prominent in Alzheimer disease but not in prion diseases in vivo. J Neuropathol Exp Neurol (2006) 1.49
Comparison of methods for profiling O-glycosylation: Human Proteome Organisation Human Disease Glycomics/Proteome Initiative multi-institutional study of IgA1. Mol Cell Proteomics (2009) 1.45
Identification of protein components in human acquired enamel pellicle and whole saliva using novel proteomics approaches. J Biol Chem (2002) 1.44
Successful pregnancy and lactation outcome in a patient with Gaucher disease receiving enzyme replacement therapy, and the subsequent distribution and excretion of imiglucerase in human breast milk. Clin Ther (2010) 1.43
LC-MS-based method for the qualitative and quantitative analysis of complex lipid mixtures. J Lipid Res (2006) 1.42
Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol (2008) 1.42
Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. Cold Spring Harb Perspect Biol (2011) 1.41
COG8 deficiency causes new congenital disorder of glycosylation type IIh. Hum Mol Genet (2007) 1.41